Literature DB >> 22278625

Osteoprotegerin, but not osteopontin, as a potential predictor of vascular calcification in normotensive subjects.

Ewa Stępień1, Danuta Fedak, Piotr Klimeczek, Tadeusz Wilkosz, Robert Paweł Banyś, Katarzyna Starzyk, Marta Bazanek, Mieczysław Pasowicz.   

Abstract

We conducted a cross-sectional observation study that included 500 asymptomatic subjects to investigate the relationship between bone metabolism and coronary artery calcification (CAC) in hypertensive conditions. Osteoprotegerin (OPG) and osteopontin (OPN) levels and their associations with hypertension were analyzed to predict CAC in 316 subjects. Multislice computed tomography was used to quantify CAC. Multivariate analysis of variance was used to test the non-interactive effects of hypertension, CAC severity and biomarker levels, and the logistic regression model was applied to predict the risk of CAC. OPG and OPN concentrations were significantly higher in the hypertensive than the normotensive subjects, at 3.0 (2.3-4.0) pmol l(-1) and 51 (21-136) ng ml(-1) vs. 2.4 (2.0-3.0) pmol l(-1) and 41 (13-63) ng ml(-1), respectively. The OPG level, but not OPN level, increased with age (r = 0.29; P = 0.0001). Zero or minimal CAC (<10 Agatston units (AU)) was observed in 63% of the subjects, mild (11-100 AU) in 17%, moderate (101-400 AU) in 12% and severe (401-1000 AU)-to-extensive (>1000 AU) in 8%. In hypertensive subjects, only glomerular filtration rate (GFR) (β = -0.67) and gender (β = 0.52) were significant predictors for CAC (R = 0.68). In normotensive patients, GFR (β = -0.81), gender (β = 0.48) and log-transformed OPG levels (β = 0.15) were significant predictors for CAC. OPG levels were associated with an increased risk of CAC in normotensive subjects only (odds ratio: 3.37; 95% confidence interval (1.63-6.57); P = 0.0002). OPG predicted a premature state of vascular calcification in asymptomatic normotensive individuals, and renal function significantly contributed to this process in both hypertensive and normotensive subjects.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22278625     DOI: 10.1038/hr.2011.231

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  7 in total

1.  Liver Fat Is Associated With Markers of Inflammation and Oxidative Stress in Analysis of Data From the Framingham Heart Study.

Authors:  Zachary P Fricker; Alison Pedley; Joseph M Massaro; Ramachandran S Vasan; Udo Hoffmann; Emelia J Benjamin; Michelle T Long
Journal:  Clin Gastroenterol Hepatol       Date:  2018-11-23       Impact factor: 11.382

Review 2.  Serum biomarkers for arterial calcification in humans: A systematic review.

Authors:  Nienke M S Golüke; Marit A Schoffelmeer; Annemarieke De Jonghe; Mariëlle H Emmelot-Vonk; Pim A De Jong; Huiberdina L Koek
Journal:  Bone Rep       Date:  2022-06-18

3.  Osteoprotegerin is a Better Serum Biomarker of Coronary Artery Calcification than Osteocalcin in Type 2 Diabetes.

Authors:  Raelene E Maser; M James Lenhard; Michael B Sneider; Ryan T Pohlig
Journal:  Endocr Pract       Date:  2015-01       Impact factor: 3.443

Review 4.  Osteoprotegerin in Cardiometabolic Disorders.

Authors:  C Pérez de Ciriza; A Lawrie; N Varo
Journal:  Int J Endocrinol       Date:  2015-05-11       Impact factor: 3.257

5.  The association of plasma osteoprotegerin levels and functional outcomes post endovascular thrombectomy in acute ischemic stroke patients: a retrospective observational study.

Authors:  Moo-Seok Park; Jin-Hee Park; Ahran Joo; Yoonkyung Chang; Tae-Jin Song
Journal:  PeerJ       Date:  2022-05-03       Impact factor: 3.061

6.  Multimarker approach in discriminating patients with symptomatic and asymptomatic atherosclerotic carotid artery stenosis.

Authors:  Piotr Musialek; Wieslawa Tracz; Lukasz Tekieli; Piotr Pieniazek; Anna Kablak-Ziembicka; Tadeusz Przewlocki; Ewa Stepien; Przemyslaw Kapusta; Rafal Motyl; Jakub Stepniewski; Anetta Undas; Piotr Podolec
Journal:  J Clin Neurol       Date:  2013-07-01       Impact factor: 3.077

7.  Osteoprotegerin and TRAIL in Acute Onset of Atrial Fibrillation.

Authors:  Krzysztof Rewiuk; Tomasz Grodzicki
Journal:  Biomed Res Int       Date:  2015-10-04       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.